Ganciclovir CAS 82410-32-0 API BW 759 GCV Antiviral CMV Inhibitor

Description:

Nomen chemicum: Ganciclovir

CAS: 82410-32-0

Aspectus: Alba ad Off-White Crystalline pulveris

Intenta: 98.0%~ 102.0%

Antiviral Agens Curatio Cytomegalovirus (CMV)

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple cum High puritate et stabulo Quality
Nomen chemicum: Ganciclovir
CAS: 82410-32-0
Antiviral agens pro curatione Cytomegalovirus (CMV)
API High Quality, Commercial Production

Chemical Properties:

Nomen chemicum	Ganciclovir
Synonyma	GCV;BW 759;9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine;2-Amino-9-(1,3-dihydroxypropan-2-yloxymethyl) -3H-purin-6-unum;2'-Nor-2'-Deoxyguanosine
CAS Number	82410-32-0
CATTUS Number	RF-API82
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C9H13N5O4
M. Pondus	255.23
Liquescens punctum	250℃
Repono Temperature	2-8℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White Crystalline pulveris
Solubilitas	Leviter solutum in aqua
Lepidium sativum	Absorptio Ultraviolet, Absorptio infrared
Damnum in Siccatio	≤6.0%
Residere in Ignition	≤0.10%
Substantiae cognatae	Ganciclovir Related Compone A ≤0.50%
Limit of Guanine	≤0.50%
RELICTUM Solvents (GC)	Ethanol ≤5000ppm
Metalla gravis	≤10ppm
effusio Coefficientis	516-548 ad 252nm .
Bacterial Endotoxins	≤0.84EU/mg
Assay	98.0%~ 102.0% (Titration)
Test Standard	Enterprise Latin;Pharmacopoeia Civitatum Foederatarum (USP) Standard
Consuetudinem	API, CMV Inhibitor

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Ganciclovir (CAS 82410-32-0) pertinet ad medicamenta nucleosida antiviralia, quaedam derivata guanosina.Ganciclovir est agentis antiviralis parenteraliter-activum indicatum ad aspectum vel cytomegalovirum (CMV) contagionum in aegros immunocompromissorum.Inhibitoriae effectus in herpes virus latum effectum habet et medicamentum primum electum est ad infectionem cytomegalovirorum tractandam cum effectu valido in virus et adenovirum hepatitis B.Est homologus acycloviri (ACV) cum effectu antivirali similis ac, sed fortior quam aciclovir, effectus inhibitores praesertim validos in cytomegaloviro cum AIDS aegris sociatis.Usus clinicus est ad tractationem inductionis periodi et periodi conservationis in aegris immunocompromissis (inclusis AIDS aegris) cum cytomegaloviro retinitis concurrente.Potest etiam adhiberi ad praecavendam morbum cytomegaloviri aegros recipiendi organum transplantationis vel AIDS aegros cum fructu positivo in testo serologiae cytomegaloviro.

Ganciclovir (CAS 82410-32-0) valde efficax, humilis-toxicitas et summus selectivity virus inhibitoris a Syntex Company (United States) evolvit.Primum medicamentum, quod ab FDA US approbatum est, ad infectionem cytomegaloviri (CMV) tractandam est.Syntexi concessum est exclusivo iure productionis.Mense Iunio 1988, tabula haec primum in UK recensenda probata est, deinde successive approbata est per Gallias, Civitates Americae Unitas, Iaponiam, et Germaniam Occidentalem, Italiam et Canadam et alias regiones.Usque ad finem mensis Iunii anno MCMXCIX approbata est in plus quam 70 terris et regionibus propter immunitatem ne aegrorum et cytomegalovirorum contagione aegrorum organi translationis.Anno 2002, tabulae Ganciclovir approbationem FDA consecuti sunt, nunc praesto fiunt.